The type, size and duration of vaccination zones I and II set out in Parts B and A of Annex II to Implementing Decision (EU) 2025/1708 are based on the epidemiological situation as regards infection with lumpy skin disease virus and the progress of the vaccination campaigns in France, particularly taking into account the evolving level of vaccine coverage achieved, the Member State’s official vaccination plan, and the progress reports submitted in accordance with Article 11 of Delegated Regulation (EU) 2023/361, as well as on the requirements laid down in Annex IX to that Delegated Regulation.
Recital 8, Decision_act (EU) 2026/662
In forcesince 13 Mar 2026